{"filing":{"accession_number":"0001575872-26-000418","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"rdy0907_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000418/rdy0907_6k.htm"},"events":[{"id":12290,"run_id":10855,"accession_number":"0001575872-26-000418","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This is a material product launch in the oncology segment with 180-day generic drug exclusivity, targeting a market with approximately $253.8 million in annual sales for the branded equivalent. The disclosure is a strategic operational milestone—a new product commercialization—rather than a discrete financial event (earnings, debt, M\u0026A) or governance matter, making it operational_other.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9099,"accession_number":"0001575872-26-000418","item_number":"EX-99.1","item_title":"rdy0907_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This is a material product launch in the oncology segment with 180-day generic drug exclusivity, targeting a market with approximately $253.8 million in annual sales for the branded equivalent. The disclosure is a strategic operational milestone—a new product commercialization—rather than a discrete financial event (earnings, debt, M\u0026A) or governance matter, making it operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:34:15.951804+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9099,"accession_number":"0001575872-26-000418","item_number":"EX-99.1","item_title":"rdy0907_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This is a material product launch in the oncology segment with 180-day generic drug exclusivity, targeting a market with approximately $253.8 million in annual sales for the branded equivalent. The disclosure is a strategic operational milestone—a new product commercialization—rather than a discrete financial event (earnings, debt, M\u0026A) or governance matter, making it operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:34:15.951804+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-06-15"}]}